source
- FDA approves adjuvant atezolizumab for MRD-positive muscle-invasive bladder cancerThe U.S. Food and Drug Administration has granted approval for adjuvant atezolizumab in patients with muscle‑invasive bladder cancer who test positive for circulating tumor DNA, indicating molecula…
- Expert outlines sequencing strategies for relapsed/refractory multiple myeloma amid rise of T-cell redirecting therapiesDr. Diana Cirstea, a specialist in multiple myeloma, explained how treatment sequencing is evolving for patients with relapsed or refractory disease. She highlighted that the growing availability o…